This article is more than 5 years old. Information may no longer be current.
NVC-422 shows promise against ophthalmic viral pathogens
Click Here to Manage Email Alerts
A study recently published in Investigative Ophthalmology & Visual Science has shown that a new-generation N-chlorotaurine-based molecule has broad-spectrum activity against major causes of viral conjunctivitis, according to a press release from NovaBay, the antiviral’s creator.
NVC-422 was tested against several serotypes of human viruses in standard in vitro titer reduction assays with and without tears, according to the study abstract. “NVC-422 has potent, rapid in vitro virucidal activity against major causes of conjunctivitis,” the researchers concluded.
“Currently, there is no U.S. Food and Drug Administration-approved drug available for the treatment of adenoviral conjunctivitis,” Dmitri Debabov, PhD, study author, told Primary Care Optometry News. “In this study we demonstrated that NVC-422 has broad-spectrum activity against major ophthalmic viral pathogens, including adenovirus, coxsackievirus, enterovirus and HSV-1.”
NovaBay reported that it is conducting a global phase 2b trial to investigate a formulation of NVC-422 to treat viral conjunctivitis. The study will enroll 450 patients with adenoviral conjunctivitis in the U.S., India and Brazil.
“BAYnovation is designed to evaluate NVC-422’s efficacy in eliminating the adenoviral infection, specifically treating the associated red eye, clearing the blurred vision and reducing the lingering effects left by the adenoviral conjunctivitis,” the press release said.